Association of polymorphisms in TGFB1 and prostate cancer prognosis

Journal of Urology

Volumn 179, Issue 2, 2008, Pages 754-758

  Brand, Timothy C ^a   Bermejo, Carlos ^a   Canby Hagino, Edith ^a   Troyer, Dean A ^b   Baillargeon, Jacques ^c   Thompson, Ian M ^a   Leach, Robin J ^a,b   Naylor, Susan L ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Polymorphism, single nucleotide; Prostate; Prostatic neoplasms; Risk factors; Transforming growth factor beta

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CHI SQUARE TEST; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; ETHNICITY; EUROPEAN AMERICAN; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLEASON SCORE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RACE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; CAUCASIAN; COHORT ANALYSIS; ETHNIC GROUP; ETHNOLOGY; GENETICS; PATHOLOGY; PROSTATE TUMOR;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 38849101142     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.09.020     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43.
2. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239.
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969.
4. Troyer D: Emerging biomarkers in prostate cancer. Aging Health Future Med 2006; p 579.
5. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644.
6. Balmain A, Gray J and Ponder B: The genetics and genomics of cancer. Nat Gen, suppl., 2003;33:238.
7. Park KH, Lo Han SG, Whang YM, Lee HJ, Yoo YD, Lee JW et al: Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a Korean population. Cancer Genet Cytogenet 2006;169:39.
8. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR et al: A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610.
9. Kambhampati S, Ray G, Sengupta K, Reddy VP, Banerjee SK and Van Veldhuizen PJ: Growth factors involved in prostate carcinogenesis. Frontiers Biosci 2005;10:1355.
10. Zhu B and Kyprianou N: Transforming growth factor beta and prostate cancer. Cancer Treat Res 2005;126:157.
11. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM et al: Preoperative plasma levels of transforming growth factor beta (1) (TGF-beta (1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856.
12. Ewart-Toland A, Chan JM, Yuan J, Balmain A and Ma J: A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prevent 2004;13:759.
13. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al: AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag 2002.
14. Shin A, Shu XO, Cai Q, Gao YT and Zheng W: Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prevent 2005;14:1567.
15. Barrett JM, Rovedo MA, Tajuddin AM, Jilling T, Macoska JA, MacDonald J et al: Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII. Prostate 2006;66:632.
16. Xu L and Bergan RC: Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway. Mol Pharmacol 2006;70:869.
17. Song K, Krebs TL and Danielpour D: Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression. Mediation by stabilization of TGF-beta receptor type II. J Biol Chem 2006;281:7765.
18. Lu S and Dong Z: Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells. Prostate 2006;66:996.
19. Rentsch CA, Cecchini MG, Schwaninger R, Germann M, Markwalder R, Heller M et al: Differential expression of TGFbeta stimulated clone 22 in normal prostate and prostate cancer. Int J Cancer 2006;118:899.
20. Pinkas J and Teicher BA: TGF-beta in cancer and as a therapeutic target. Biochem Pharmacol 2006;72:523.